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ABSTRACT
Introduction. Recombinant granulocyte colony-stimulating factor (G-CSF) may aid engraftment post high-dose
chemo-/radiotherapy in patients with haematological malignancies undergoing allogeneic bone marrow transplan-
tation (BMT); however, the effects of G-CSF on graft-versus-host disease (GvHD), relapse, and survival are not well
deﬁned.
Methods. In this double-blind, randomized, placebo-controlled, multicentre, phase 3 study, the effects of the G-CSF
Filgrastim on neutrophil and platelet recovery, and on clinical outcomes were evaluated. Patients (12–55 years)
receiving an allogeneic BMT for a haematological malignancy were randomized to receive Filgrastim 5 mg/kg or
placebo. Study treatment was continued until patients achieved an absolute neutrophil count (ANC) 0.5 ¥ 10
9/L,
or until day 42.
Results. Fifty-one patients (Filgrastim, N = 25; placebo, N = 26) were evaluable. Patients treated with Filgrastim
had signiﬁcantly faster engraftment with ANC 0.5 ¥ 10
9/L being achieved after a median (range) of 15.0 (1.0–22.0)
days vs. 19.0 (15.0–28.0) days for placebo (P < 0.0001). The incidence of GvHD was comparable for both groups.
During the limited follow-up (2 years), Filgrastim had no adverse effect on mortality and possibly reduced the rate
of relapse.
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Introduction
T
he success of allogeneic haemopoietic stem
cell transplantation is inﬂuenced by several
factors such as: efﬁciency of the procedure to
eradicate disease, age of the patient, immune
reactions following transplantation of cells, and
adverse reactions to conditioning treatment. In
patients with chronic myeloid leukaemia, it has
been shown that mortality post-bone marrow
transplant (BMT) can vary from 22% to 72% at 5
years depending on the number of adverse risk
factors [1]. Additional risk factors for mortality
include infections that arise as a result of neutro-
penia and prolonged immune deﬁciency. Recom-
binant human granulocyte colony-stimulating
factor (G-CSF) or granulocyte macrophage
colony-stimulating factor (GM-CSF) may be
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either bone marrow or peripheral blood stem
cells to enhance engraftment [2–7]. Some authors
report that patients receiving growth factors post
allogeneic stem cell transplant experience faster
neutrophil recovery and no adverse effects in
terms of graft versus host disease (GvHD) [4,8].
Nevertheless, the effects of G-CSF on longer-
term outcomes in this setting are not well deﬁned
and have been the subject of debate [9–11]. Two
retrospective analyses suggest that G-CSF treat-
ment after allogeneic stem cell transplant may
have a negative impact on outcome with increased
risk of GvHD and reduced survival [10,12].
With the aim of providing further information
on the use and safety of G-CSF in this setting, we
have returned to a previously unpublished phase 3,
placebo-controlled trial of Filgrastim adminis-
tered after allogeneic BMT in patients with hae-
matological malignancies. Although the study was
terminated in 1998 due to slow recruitment, the
prospective nature of the data collected means that
the present paper contributes to our knowledge
about the safety of G-CSF in this setting.
Patients and Methods
Patients
This trial was conducted in compliance with the
Declaration of Helsinki. The ethical committee at
each participating site approved the study proto-
col. Written informed consent was obtained prior
to study entry.
Eligible patients were aged 12–55 years with a
diagnosis of acute lymphoblastic leukaemia (ALL)
or lymphoblastic lymphoma (deﬁned as T convo-
luted [Lukes-Collins Classiﬁcation], lymphoblas-
tic lymphoma [Kiel, Rappaport Classiﬁcation],
or undifferentiated [Lukes-Collins Classiﬁcation])
who were in complete remission; high-risk non-
Hodgkin’s lymphoma (NHL) (Kiel, Rappaport
Classiﬁcation) in second remission; acute myeloid
leukaemia (AML) in ﬁrst or second remission; or
chronic myeloid leukaemia (CML) in a chronic or
accelerated phase. Patients had to have an Eastern
Co-operative Oncology Group (ECOG) score of
0–2 or a Karnofsky score from 100–60.
Patients were scheduled to receive at least
2 ¥ 10
8 nuclear cells/kg from an HLA-matched
sibling bone marrow donor following either:
cyclophosphamide 60 mg/kg/day for 2 days (total
dose 120 mg/kg) and total body irradiation (at
least 1,000 cGy); or etoposide 60 mg/kg for 1 day
(total dose 60 mg/kg) and total body irradiation
1,200 cGy; or busulphan 4 mg/kg for 4 days
(total dose 16 mg/kg) and cyclophosphamide at
60 mg/kg for 2 days (total dose 120 mg/kg) with
or without etoposide 30–45 mg/kg for 1 day (total
dose 30–45 mg/kg). Patients were required to have
serum creatinine and serum bilirubin levels less
than 2.5 times the upper limit of normal.
Patients with a history of another malignancy,
other than adequately treated carcinoma of the
skin or cervical cancer (stage I), were ineligible, as
were patients with active infections, and patients
who had used antimicrobials within 72 hours prior
to treatment. Congestive heart failure (NYHA
class III–IV) precluded entry to the study, as
did uncontrolled hypertension, multifocal cardiac
arrhythmias or unstable angina. Pregnant or lac-
tating women were also excluded, and those of
childbearing age were required to have been prac-
ticing adequate contraception.
Study Drug
Filgrastim and an identically packaged placebo for
subcutaneous administration were manufactured
and packaged by Amgen Inc. (Thousand Oaks,
CA, USA) and distributed through F. Hoffmann-
LaRoche (Basel, Switzerland). The Filgrastim
preparation was a sterile aqueous buffered protein
solution containing 0.3 mg/mL of Filgrastim.
The placebo preparation contained the same
sterile aqueous buffered protein solution without
Filgrastim.
Study Design
This was a phase 3, multicentre, randomized,
double-blind, placebo-controlled study. Random-
ization was stratiﬁed by age (<18 years and 18
years) and remission status (ﬁrst complete remis-
sion and subsequent remissions) at each centre.
Patients were randomly assigned using Pocock and
Simon’s minimization procedure at a 1:1 ratio to
receive bolus injections of either Filgrastim at
5 mg/kg/day or placebo for up to 42 days begin-
ning on the day of allogeneic BMT.
Infection prophylaxis, parenteral feeding and
other supportive care were performed according
to the policies of the individual study site. Neutro-
penic patients were treated with a protocol deﬁned
regimen or according to local practice. Patients
with engraftment failure on day 35 could be
unblinded and treated with open-label Filgrastim
for engraftment failure (these patients were cen-
sored on day 35 for the primary endpoint).
Engraftment failure was deﬁned as an absence of
absolute neutrophil count (ANC) 0.5 ¥ 10
9/L on
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reduced transfusion requirements for platelets
and red blood cells. Study medication was to be
discontinued if the ANC was 1.0 ¥ 10
9/L for 3
consecutive days and reintroduced when ANC
subsequently dropped below 1.0 ¥ 10
9/L for 2
consecutive days. All patients received GvHD pro-
phylaxis as per standard protocol at each centre
(cyclosporine plus methotrexate in all cases). If no
GvHD was present, this regimen was tapered off
at day 100. GvHD was treated using the standard
individual centre regimen.
Efﬁcacy Endpoints and Safety Analysis
The predetermined primary efﬁcacy endpoint was
the time to ANC of 0.5 ¥ 10
9/L, and the time to
ANC 1.0 ¥ 10
9/L was also evaluated. The sec-
ondary efﬁcacy endpoints for the immediate post-
transplant period were: time to discharge from
semi-sterile conditions; the number of days of
fever, neutropenic fever, and antibiotic use
(excluding prophylactic antibiotics); the duration
of neutropenia; the time to platelet recovery of
25 ¥ 10
9/L and 50 ¥ 10
9/L, and the number of
days with platelets <25 ¥ 10
9/L and <50 ¥ 10
9/L.
After hospital discharge, patients were followed
up at weekly intervals for 6 weeks, alternate weeks
thereafter for 1 month, and every 3 months for 2
years following allogeneic BMT. During this time
period, data were collected on GvHD, and safety
was assessed as the incidence and severity of
adverse events and as changes in laboratory tests.
Additional parameters included overall survival
(deﬁned as the time from transplantation day until
death or until the day of last follow-up) and
relapse-free survival (deﬁned as the time from
transplantation day until clinical diagnosis of
relapse). Conventional haematological criteria
were used to deﬁne remission status. The criteria
for remission status included establishment of a
normal bone marrow cell karyotype, and imm-
unoglobulin gene or T-cell receptor gene
rearrangement.
Statistical Analysis
At least 40 evaluable patients (20 per treatment
group) were required to ensure a probability of
at least 80% of detecting a difference of at least
3.6 days between treatment groups in the primary
efﬁcacy endpoint of time to ANC recovery
(ANC  0.5 ¥ 10
9/L) using the log-rank test with
a two-tailed signiﬁcance level of 5% and assuming
a standard deviation of 3.8 days. The target of 100
evaluable patients (50 per treatment group) was set
to provide 80% probability of detecting a differ-
ence of 3.6 days between groups in the secondary
endpoint of time to release from semi-sterile con-
ditions, using the log-rank test with a two-tailed
signiﬁcance level of 5% and assuming a standard
deviation of 5.8 days.
An interim analysis was planned for the point
when 40 patients had been followed for at least 100
days post BMT. In this analysis, the time to ANC
recovery was compared between groups using the
log-rank test and a two-tailed signiﬁcance level of
4.8%.
Quantitative parameters were summarized by
the mean, standard deviation, median, upper and
lower quartiles, and the range (minimum and
maximum values). Non-parametric statistical
analysis methods were used to compare treatment
groups. For all endpoints, excluding time-to-event
endpoints, the treatment groups were compared
using the Mann-Whitney test. For time-to-event
endpoints, the data were analysed using the log-
rank test.
Results
Interim Analysis
The study was initiated in January 1993 and an
interim analysis was performed as planned in
March 1996. This analysis showed a statistically
signiﬁcant and clinically relevant difference in
favour of Filgrastim over placebo in the time to
ANC recovery. The median (range) time to
ANC  0.5 ¥ 10
9/L was 15.0 (1.0–22.0) days for
Filgrastim (N = 18) compared with 19.0 (15.0–
28.0) days for placebo (N = 19) (P < 0.0001). No
statistically signiﬁcant difference was observed in
the median time to discharge from semi-sterile
conditions (Filgrastim: 24.0 [14.0–43.0] vs.
placebo: 28.0 [19.0 vs. 43.0] days; P = 0.8213).
Final Analysis—Patient Disposition and
Baseline Characteristics
Between January 1993 and November 1996, a total
of 66 patients were enrolled in the study from
seven centres located in Germany (two centres),
Saudi Arabia (two centres), Finland, Italy, and
Sweden. Recruitment was slow and no further
patients were randomized after November 1996.
Patients were followed up until March 1998, when
the study was closed.
Fifteen patients had major protocol violations:
Filgrastim treatment not according to protocol
(N = 5); nuclear cells <2.0 ¥ 10
8/L (N = 3);
Efficacy of Filgrastim Post Allogeneic BMT 91
Arch Drug Info 2008;1:89–96missing data (N = 2); two bone marrow transfu-
sions (N = 1); no BMT (N = 1); inappropriate
conditioning regimen (N = 1); inappropriate dis-
charge conditions (N = 1); received commercial
drug (N = 1). These patients were excluded from
the efﬁcacy and safety analyses, which conse-
quently contained 51 patients (Filgrastim, N = 25;
placebo, N = 26).
Patient baseline demographics and disease
characteristics are shown in Table 1. The treat-
ment groups were generally well-balanced,
although the placebo group had a higher propor-
tion of men and higher mean weight. The most
common diagnosis in both groups was ALL, and
the most common remission status was ﬁrst com-
plete remission. The stratiﬁcation of patients by
age and remission status resulted in a good
balance between the groups with regard to these
parameters.
Neutrophil Recovery and Related Parameters
In the ﬁnal analysis of the primary endpoint, the
median (Q1, Q3) number of days to achieve
ANC  0.5 ¥ 10
9/L was 15.0 (13.0, 16.0) days in
the Filgrastim group, compared to 19.0 (17.0,
22.0) days in the placebo group. Faster recovery
of neutrophil counts in patients receiving
Filgrastim was also evident in a time to event
analysis (Figure 1). Similarly, the median (Q1,
Q3) number of days to achieve ANC 
1.0 ¥ 10
9/L was 16.0 (15.0, 17.0) days in the
Filgrastim group, compared to 22.0 (21.0, 28.0)
days in the placebo group. For both variables, the
differences between Filgrastim and placebo were
statistically signiﬁcant (P < 0.0001 vs. placebo;
Table 2).
The median time to discharge from semi-sterile
conditions, median number of days with neutro-
penic fever and median number of days of IV
antibiotic use, were all numerically lower with
Filgrastim than with placebo. The differences
between treatment groups did not, however, reach
statistical signiﬁcance for any of these endpoints
(Table 2).
Table 1 Baseline demographics and disease
characteristics
Filgrastim
(N = 25)
Placebo
(N = 26)
Men, N (%) 13 (52%) 21 (81%)
Mean (SD) age (years) 28.2  10 27.4  10
Mean (SD) weight (kg) 59.8  15 68.7  16
Diagnosis, N (%)
Acute lymphatic leukaemia (ALL) 18 (72%) 17 (65%)
Biphenotypic leukaemia 0 (0) 1 (4%)
Acute myeloid leukaemia (AML) 2 (8%) 3 (12%)
Chronic myeloid leukaemia (CML) 5 (20%) 4 (15%)
Lymphoblastic lymphoma 0 (0) 1 (4%)
Remission Status, N (%)
Complete remission* 5 (20%) 8 (31%)
First complete remission 13 (52%) 11 (42%)
Second complete remission 2 (8%) 2 (8%)
Third complete remission 0 (0) 1 (4%)
First chronic phase 2 (8%) 1 (4%)
Accelerated phase 1 (4%) 1 (4%)
Second chronic phase 1 (4%) 0 (0)
None provided 1 (4%) 2 (8%)
*Number of complete remission not speciﬁed for these patients.
Figure 1 Kaplan-Meier analysis of
time to recovery of absolute neutrophil
count in patients receiving ﬁlgrastim
vs. placebo.
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It transpired that investigators had stopped re-
cording platelet counts after ANC recovery—
an event that occurred more rapidly for those
receiving Filgrastim. Consequently, many
patients with “low” platelet counts at last assess-
ment may in fact have reached recovery thresh-
olds within the 42-day follow-up period, but this
is impossible to determine, thus the platelet data
are confounded and are not reported in this
manuscript.
Graft-versus-host Disease
About half of the patients in both treatment arms
remained free of acute GvHD throughout the
whole study (Table 3). Among those patients
that exhibited acute GvHD, most experienced
maximum grade 1 disease but a few patients in
each group displayed grade 2 or 3 disease
(Table 3). The number of days to ﬁrst presentation
with acute GvHD and the number of days to worst
acute GvHD were also similar between the treat-
ment groups. Overall, the data indicate no differ-
ence in the incidence and severity of acute GvHD
between patients receiving Filgrastim and those
receiving placebo. The incidence of physician-
reported chronic GvHD was similar between the
groups (Table 3).
Overall Survival andTime to Relapse
During the observation period (maximum of 2
years post-BMT), 4 (16%) patients in the
Filgrastim group and 8 (31%) patients in the
placebo group died (Table 4). All deaths occurred
within 1 year of BMT. No deaths were related to
Table 2 Neutrophil recovery and related parameters
Filgrastim
(N = 25)
Placebo
(N = 26)
Time to recovery of ANC  0.5 ¥ 10
9/L (N = 25) (N = 25)
Median (range), days 15.0 (1.0–22.0) 19.0 (15.0–28.0)
Q1, Q3 13.0, 16.0 17.0, 22.0
Difference 4 days
P value P < 0.0001
Time to recovery of ANC  1.0 ¥ 10
9/L (N = 25) (N = 25)
Median (range), days 16.0 (1.0–23.0) 22.0 (15.0–37.0)
Q1, Q3 15.0, 17.0 21.0, 28.0
Difference 6 days
P value P < 0.0001
Time to discharge from semi-sterile conditions (N = 25) (N = 26)
Median (range), days 25.0 (14.0–43.0) 28.0 (10.0–43.0)
Q1, Q3 22.0, 30.0 25.0, 33.0
Difference 3 days
P value P = 0.3304
Days with neutropenic fever (N = 25) (N = 26)
Median (range) 5.0 (0.0–16.0) 6.0 (0.0–18.0)
Q1, Q3 1.0, 16.0 0.0, 18.0
Difference 1 day
P value P = 0.2214
Days on antibiotics (N = 24) (N = 26)
Median (range) 11.5 (0.0–42.0) 18.0 (0.0–43.0)
Q1, Q3 0.0, 22.5 0.0, 28.0
Difference 6.5 days
P value P = 0.1791
Table 3 Graft versus host disease (GvHD)
Treatment group
Filgrastim
(N = 25)
Placebo
(N = 26)
Patients with acute GvHD,
N (%)
13 (52%) 12 (46%)
Number of days to ﬁrst acute GvHD
Median (range) 15.0 (7.0–47.0) 18.5 (5.0–59.0)
Q1, Q3 (14.0, 22.0) (15.0, 31.0)
Worst acute GvHD, N (%)*
N2 5 2 5
Grade 1 10 (40%) 7 (28%)
Grade 2 2 (8%) 4 (16%)
Grade 3 1 (4%) 1 (4%)
Grade 4 0 (0) 0 (0)
No GvHD 12 (48%) 13 (52%)
Number of days to worst acute GvHD
Median (range) 21.0 (7.0–47.0) 19.0 (5.0–59.0)
Q1, Q3 14.0, 29.0 15.0, 36.0
Patients with chronic GVHD,
†
N (%)
10 (40%) 12 (46%)
*Acute GvHD was graded 1–4 depending on degree of organ involvement.
Grade 1 signiﬁed no gut or liver involvement and no decrease in clinical
performance in the presence of macularpapular skin rash covering up to 50%
of body surface, and grade 4 denoted signiﬁcant gut and liver involvement, an
extreme decrease in clinical performance and desquamation of the skin.
†Physician-reported.
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Filgrastim group had a relapse, compared to 8
(31%) patients in the placebo group. The patient
in the Filgrastim group had ALL at baseline, as
did ﬁve of the patients who relapsed in the
placebo group. Other baseline diagnoses in this
group were AML (N = 2) and biphenotypic leu-
kaemia (N = 1).
Safety andTolerability
Adverse events occurred in similar proportions of
the Filgrastim and placebo groups: (19/25 [76%]
with Filgrastim vs. 19/26 [73%] with placebo).
The only event occurring with 5% greater fre-
quency in the Filgrastim group than the placebo
group was fever (6/25 [24%] vs. 4/26 [15%],
respectively). Three adverse events in the
Filgrastim group (weight change, liver disease, and
abnormal renal function) and six events in the
placebo group (fever [N = 2], weight change,
nausea, vomiting, and musculoskeletal pain) were
reported as possibly related to treatment; none of
these events were severe or life threatening. The
incidence of life-threatening adverse events was
16% (4/25) in the Filgrastim group vs. 8% (2/26)
for placebo, none were considered related to study
treatment.
Discussion
In this randomized study, patients receiving
Filgrastim post BMT had faster ANC recovery
than those receiving placebo. Furthermore, the
study suggests no difference in time to discharge
from semi-sterile conditions. ANC is the main
driver of discharge from semi-sterile conditions,
but we realize that other factors such as oral nutri-
tion and ability to take drugs by mouth may inﬂu-
ence this decision. Adverse events occurred at a
similar rate in the Filgrastim and placebo groups.
The present data broadly reﬂect previous ﬁnd-
ings with regard to the effects of growth factors on
ANC recovery post allogeneic BMT. For example,
in a trial of 40 patients randomized to 8 mg/kg/day
GM-CSF (N = 20) or placebo (N = 20), Singhal
et al. reported a signiﬁcantly faster neutrophil
recovery [8]. Furthermore, in a randomized
double-blind trial of G-CSF 10 mg/kg/day
(N = 26) vs. placebo (N = 24) administered after
allogeneic BMT, G-CSF also resulted in signiﬁ-
cantly more rapid neutrophil recovery (11 vs. 15
days for placebo, P = 0.008) [4]. More recently,
a retrospective database analysis by Khoury et al.
showed a statistically signiﬁcant reduction in time
to neutrophil engraftment for patients receiving
G-CSF following transplantation of bone marrow
from unrelated donors compared to no growth
factor support (median 16 vs. 20 days; P < 0.001)
[7].
Our main reason for returning to this prospec-
tive study was to examine data on GvHD and sur-
vival. Two retrospective analyses have questioned
whether G-CSF may be associated with a higher
incidence of immunologic reactions [10,12]. For
example, the retrospective European analysis by
Ringden et al., identiﬁed a possibly increased inci-
dence of GvHD and transplant-related mortality
in patients (N = 1,789) receiving G-CSF soon
after allogeneic BMT, as well as reduced survival
and leukaemia-free survival [10]; however no
increased rate of GvHD was observed for patients
receiving G-CSF following peripheral blood stem
cell transplant. In the previously mentioned ran-
domized study by Singhal, GM-CSF was associ-
ated with no deleterious effect on acute or chronic
GvHD, relapse or survival after 5-year follow-up
[8], while the study by Bishop also showed no
difference between G-CSF and placebo in acute
GvHD [4]. Furthermore, a meta-analysis of 18
studies involving 1,198 patients showed that
G-CSF had no effect on the incidence of acute
GvHD, chronic GvHD, transplant-related mor-
tality or survival [13]. These ﬁndings have since
been corroborated by another retrospective data-
base analysis including 1,435 bone marrow recipi-
ents [7] and a further meta-analysis of studies in
patients undergoing either allogeneic or autolo-
gous stem cell transplant [14].
Within the limits of the current dataset there
was no difference in the incidence or severity of
Table 4 Deaths and causes of death according to
treatment group
Treatment group
Filgrastim
(N = 25)
Placebo
(N = 26)
Patients with 1 cause of death, N (%) 4 (16%) 8 (31%)
Causes of death, N
Heart failure 1
Haemorrhage 1
Multiorgan failure 1
Sepsis 1
Disease progression 3
Leukaemia 1
Neurological disorders 1
Respiratory tract infection 1
Unknown diagnosis/not speciﬁed 1 2
NB. One patient in the Filgrastim group had two designated causes of
death—heart failure and sepsis.
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compared with placebo, nor was there any adverse
effect on mortality or relapse. Fewer patients
experienced relapse in the Filgrastim group com-
pared with placebo. Any potential beneﬁt from
Filgrastim in terms of relapse could be the result of
stem cell competition: the earlier engraftment and
graft function experienced with Filgrastim support
may favour donor cells competing with leukaemia
cells of the recipient [15]. It is also a possibility,
however, that the placebo group contained a
greater proportion of patients at high risk of
relapse. For example, this arm was more heavily
weighted with males, who tend to have poorer
outcomes than females in allogeneic BMT. The
effect of Filgrastim on relapse needs to be explored
in a study adequately powered for this endpoint.
Our ﬁndings are limited by early termination of
the study and the small number of patients ran-
domized. The slow recruitment that forced termi-
nation may have been related to an unwillingness
to randomize patients to placebo; widespread use
of Filgrastim in this setting could have meant that
it was already accepted as the standard of care.
Furthermore, mortality and relapse data must be
interpreted within the context of the high propor-
tion of censored patients and the limited follow-
up period. Although clinical practice may have
changed since this study was conducted, these pro-
spective, blinded data are not subject to the poten-
tial biases of retrospective studies, and provide
further information on the safety of G-CSF post
allogeneic BMT.
In conclusion, the present study provides pro-
spective data indicating that the G-CSF Filgrastim
is associated with signiﬁcantly more rapid neutro-
phil recovery than placebo in patients undergoing
allogeneic BMT. Filgrastim had no detrimental
effect on acute GvHD, while the potential effect of
Filgrastim therapy with regard to relapse requires
further investigation.
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